Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AmiNA: Neoadjuvant Amivantamab in Resectable EGFR-Mutated NSCLC
NCT07586202Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Mar 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of amivantamab in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Jul 2026; status: recruiting.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07586202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07586202.